NewAmsterdam Pharma Company NAMS Enterprise value

Enterprise value at other companies

Merck & Co.MRK

$367.21B+59.3%

AmgenAMGN

$252.17B+23.1%

Regeneron PharmaceuticalsREGN

$65.61B+15.0%

RFL

Rafael Holdings, Inc.RFL

$52.06M+46.1%

Denali Therapeutics Inc.DNLI

$3.92B+96.2%

ArvinasARVN

$599.29M+45.3%

FAQ

What is NewAmsterdam Pharma Company's enterprise value?

NewAmsterdam Pharma Company (NAMS) reported enterprise value of $3.54B in Q2 2026.

How has NewAmsterdam Pharma Company's enterprise value changed year-over-year?

NewAmsterdam Pharma Company's enterprise value increased by 135.5% year-over-year, from $1.5B to $3.54B.

What is the long-term trend for NewAmsterdam Pharma Company's enterprise value?

Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's enterprise value has grown at a 89.4% compound annual growth rate (CAGR), from $513.24M to $3.49B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.